Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results

Gilead Sciences (NASDAQ:GILD) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23, Zacks reports. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences updated its FY 2025 guidance to 7.700-8.100 EPS.

Gilead Sciences Trading Up 0.7 %

Shares of Gilead Sciences stock traded up $0.66 during trading on Tuesday, hitting $96.14. 6,151,322 shares of the company were exchanged, compared to its average volume of 6,984,431. The firm has a market capitalization of $119.82 billion, a P/E ratio of 1,068.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The firm’s fifty day moving average price is $93.07 and its 200 day moving average price is $86.99. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $100.51.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wolfe Research started coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. BMO Capital Markets increased their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Citigroup started coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.